Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT | BSE: 524742 | ISIN: INE475E01026 |Industry: Pharmaceuticals
|Expensive Performer

Caplin Point Laboratories Ltd.    
02 Nov 2021, 01:20PM

Key Highlights (Consolidated):

  • Cash Reserves at Rs. 562 Cr
  • Revenue for the H1FY22 grew by 20% YoY to Rs. 622cr. 
  • Gross margin for half year expanded by 176 bps YoY to 56.7% whereas for the quarter the gross margins expanded by 345bps YoY to 58.6%
  • H1FY22 PAT was at Rs. 148cr. up 26.4% YoY
  • Cash and Cash Surplus at Rs. 562cr. as at end of September 2021 - increase of Rs 92 Cr over March 2021 balance. 
  • Free cash flow stood at Rs. 103 Cr as at Sep 21
  • Receivable days stable at 93 days as on Sep 21
  • Q2 FY22 Revenue at Rs. 312 Cr, up 15.6% YoY, as compared to Rs. 270 Cr in Q2 FY21
  • H1FY22 Revenue up 20% YoY,
  • PAT up 26% YoY 
  • Gross Margins improved to 58.6% in Q2FY22 from 55.1% in Q2FY21 and 54.7% in Q1FY22
  • PAT increased by 26.4% to Rs. 148 Cr in H1FY22 against Rs. 117 Cr in H1FY21 
  • PAT for the quarter was at Rs. 77cr. up 22% as compared to Rs. 63cr in Q2FY21
  • Cash flow From Operations at Rs 131cr. in H1FY22 as against Rs 266 Cr for the whole year FY21
  • Basic EPS grew by 31% to Rs. 19.28 in H1FY22 against Rs. 14.73 in H1FY21 (not Annualized)
  • With depreciation of INR against USD, exchange gain in H1FY22 is Rs. 5.33cr and for Q2 FY22 is Rs. 1.75 Cr as against exchange loss of Rs. (2.01) Cr in H1FY21 and Rs. (3.77) Cr in Q2 FY21
  • With continued focus on Cash Flow, Receivables sustained at 93 days despite growth in sales 
  • Inventory stood at Rs. 237cr (including transit inventory of Rs.126 Cr) in Sep 21 as against Rs. 193 Cr in June 21. 
  • Geographical breakup of sales: LATAM & ROW - 90%, US – 10%



Result PDF

Caplin Point Laboratories Ltd. is trading above it's 200 day SMA of 684.0
More from Caplin Point Laboratories Ltd.